Skip to content

Telehealthcare in the Southeast of Sweden – a study on cost-effectiveness

The eKOL study: a randomised multi-centre study on telehealthcare of patients with chronic obstructive pulmonary disease in Southeast Sweden – a study on cost-effectiveness

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16832751
Enrollment
200
Registered
2022-11-02
Start date
2020-10-22
Completion date
Unknown
Last updated
2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of exacerbations of chronic obstructive pulmonary disease (COPD) leading to hospitalisation Respiratory

Interventions

Patients suitable for telehealth care are randomised to either telehealth care (as a supplement to standard health care) or not (control) and followed for at least 1 year (maximum 2 years). Depending

Sponsors

County Council of Östergötland
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. A patient offered telehealthcare service for COPD 2. Written consent to participate in the study 3. A diagnosis of COPD 4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups B, C or D, which in turn are decided by the COPD Assessment Test (CAT) score and exacerbation history at baseline according to the GOLD guidelines

Exclusion criteria

Exclusion criteria: 1. Unable to communicate because of hearing loss or difficulties understanding Swedish 2. Dementia or other cognitive disabilities and/or psychiatric disease of significance as judged by the study physician 3. Ongoing abuse of drugs (not tobacco) or alcohol 4. Other significant disease that dominates the clinical picture more than COPD as judged by the study physicians

Design outcomes

Primary

MeasureTime frame
Annual healthcare contacts and associated costs, assessed using data from journals and data from health care registers at 24 months (in some cases also at 48 months)

Secondary

MeasureTime frame
1. Annual exacerbation frequency assessed using data from journals at 24 months (in some cases at 48 months) 2. Annual survival assessed using data from journals and data from registers at 24 months (in some cases at 48 months) 3. Burden of COPD symptoms and quality of life assessed using the COPD Assessment Test (CAT) monthly during the study period (1-2 years)

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026